Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2025

Aug 01, 2025

BUY
$0.88 - $1.35 $117,081 - $179,613
133,047 New
133,047 $146,000
Q1 2024

May 10, 2024

BUY
$2.03 - $6.59 $56,947 - $184,869
28,053 New
28,053 $119,000

Others Institutions Holding PYXS

About Pyxis Oncology, Inc.


  • Ticker PYXS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,096,400
  • Market Cap $158M
  • Description
  • Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, no...
More about PYXS
Track This Portfolio

Track Y Intercept (Hong Kong) LTD Portfolio

Follow Y Intercept (Hong Kong) LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Y Intercept (Hong Kong) LTD, based on Form 13F filings with the SEC.

News

Stay updated on Y Intercept (Hong Kong) LTD with notifications on news.